Myriad Genetics Showcases AI-Driven Cancer Diagnostics at ASCO 2025
Myriad Genetics, a pioneer in molecular diagnostics, is making headway in the artificial intelligence (AI) integration applied to oncology. The company's recent milestones in AI tools introduced in oncology at the 2025 Annual Meeting of the American Society of Clinical Oncology, bear testimony to Myriad's continuing endeavour for precision medicine.
AI-Powered Prostate Cancer Prognostics
Myriad Genetics and PATHOMIQ, a company that develops AI-enabled prognostic and predictive tests, together presented the PATHOMIQ_PRAD platform, an AI technology designed to predict treatment responses and to classify for post-surgical intervention the subgroup of high-risk patients with prostate cancer; it reviews digital biopsy images to find characteristics that can be used in treatment selection.
The AI model had high prediction accuracy, surpassing some currently used markers in patient cohorts. Myriad is planning the commercial launch of this AI prostate cancer clinical test by the end of the year.
Also Read: Pathos AI Raises $365 Million to Build the World’s Largest Oncology AI Model
Advancements in Molecular Residual Disease (MRD) Testing
Moving beyond prostate cancer, Myriad spotlighted its AI-enhanced MRD assay, Precise MRD, that applies AI to detect ultra-low levels of circulating tumor DNA (ctDNA). This assay, having ultra-sensitivity, looks to find minimal residual disease in other cancers such as breast and ovarian cancers.
The AI-enabled testing means early potential relapse detection, which will empower clinicians to tailor their treatment strategies. Clinical data presented at ASCO 2025 revealed that the assay could detect ctDNA at levels never achieved with traditional techniques, thus approaching a more accurate way of measuring the presence of disease.
Myriad's dedication to AI in oncology is typified by its strategic alliance with the University of Texas MD Anderson Cancer Centre. The five-year partnership aims to expedite the development and implementation of AI-based cancer diagnostics through the integration of Myriad's advanced diagnostic technologies with the clinical expertise of MD Anderson.
Myriad Genetics' presentations at ASCO 2025 speak to the transformative prospect of AI over the cancer diagnostic stream. Through strategic partnerships and innovative technologies, Myriad is well-positioned on a path to realizing the AI vision for oncology with a view toward improving patient outcomes and furthering precision medicine.
